Skip to main content
. 2020 Jan 27;2020(1):CD010061. doi: 10.1002/14651858.CD010061.pub4

EUCTR2013‐003883‐30‐IT.

Trial name or title Efficacy and safety of paracetamol in comparison to ibuprofen for patent ductus arteriosus treatment in preterm infants. A randomised, open label, comparator‐controlled, prospective study
Methods Randomised open label controlled trial of paracetamol versus ibuprofen
Participants Preterm newborn infants (< 37 weeks' PMA)
Interventions Paracetamol and ibuprofen
Outcomes Primary end‐point: success rate in closing PDA using paracetamol in comparison to ibuprofen after the first 3 days of treatment.
Secondary endpoints: number of re‐openings at 30 days; success rate in closing PDA after the second treatment course of ibuprofen as rescue medication; success rate of closing PDA after the first day and the second day of the first treatment course; incidence of surgical ligation at 30 days; incidence of renal failure, liver failure, gastrointestinal complications (including isolated intestinal perforation) at 30 days; incidence of death at 30 days and at 40 weeks' post conception; incidence of sepsis at 30 days; hospital‐stay duration in Neonatal Intensive Care Unit; occurrence of adverse events at 30 days
Starting date November 2013
Contact information Name of Sponsor: Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A, Italy
Notes